| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05a203d85ee01909eaf728dc16f0f6cb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ecf052236214657b83ceb39abf7d67f9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3061
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7034 |
| filingDate |
2016-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b190f576613ce4a8f0bcd40d6c3f408
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93aa5bab6d96fdf3ab77ac1293a935be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd0aa63899df42468b20a5290e981fa1 |
| publicationDate |
2017-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2016202621-B2 |
| titleOfInvention |
Combination of inotuzumab ozogamicin and torisel for the treatment of cancer |
| abstract |
COMBINATION OF INOTUZUMAB OZOGAMICIN AND TORISEL FOR THE TREATMENT OF CANCER Abstract The present invention relates to a therapeutic method for the treatment of cancer that comprises the use of a combination of inotuzumab ozogamicin (CMC-544) and temsirolimus. The enhanced antitumor of the combination therapy is particularly useful for patient population that are recalcitrant to inotuzumab ozogamicin or temsirolimus therapy, relapse after treatment with inotuzumab ozogamicin or temsirolimus or where enhanced antitumor effect reduces toxicities associated with treatment using inotuzumab ozogamicin or temsirolimus. |
| priorityDate |
2011-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |